Millennium entities disclose 3% Fulgent Genetics (FLGT) stake in 13G/A filing
Rhea-AI Filing Summary
Fulgent Genetics, Inc. received an amended Schedule 13G/A (Amendment No. 4) reporting institutional ownership of its common stock. Investment entities including Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of about 3.0% of the common stock, including 939,375 shares with shared voting and dispositive power for several reporting persons and 918,503 shares for Integrated Core Strategies. The filers certify the shares were not acquired to change or influence control of Fulgent Genetics.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What ownership stake in Fulgent Genetics (FLGT) does Millennium report in this Schedule 13G/A?
The filing reports that entities associated with Millennium beneficially own about 3.0% of Fulgent Genetics common stock. Several reporting persons list 939,375 shares with shared voting and dispositive power, while Integrated Core Strategies (US) LLC lists 918,503 shares, also representing 3.0% of the class.
Who are the reporting persons in the Fulgent Genetics (FLGT) Schedule 13G/A Amendment No. 4?
The reporting persons are Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. They file jointly under a joint filing agreement and provide a shared New York business address at 399 Park Avenue, reflecting coordinated institutional ownership disclosure.
Does the Fulgent Genetics (FLGT) Schedule 13G/A indicate an intent to influence control of the company?
No. The certification states the securities were not acquired and are not held for the purpose or effect of changing or influencing control. The reporting persons characterize their holdings as passive, consistent with a Schedule 13G filing rather than an activist or control-focused Schedule 13D.
What percentage of Fulgent Genetics (FLGT) does Israel A. Englander report beneficially owning?
Israel A. Englander reports beneficial ownership of 939,375 Fulgent Genetics shares, representing 3.0% of the common stock. The filing explains these securities are held by entities subject to voting control and investment discretion structures, and expressly notes this should not itself be construed as an admission of beneficial ownership.
What is the relevant event date for the Fulgent Genetics (FLGT) Schedule 13G/A ownership information?
The event date triggering this Schedule 13G/A is December 31, 2025. Ownership figures, including the 3.0% beneficial stakes and share counts such as 939,375 and 918,503, are reported as of that event date, providing investors with a snapshot of institutional holdings at year-end 2025.